Quick answers
- What is Bimatoprost used for?
- The FDA-approved label (Latisse, Allergan, Inc., July 1, 2024) says: “LATISSE ® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. LATISSE ® is a prostaglandin analog, indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Bimatoprost have a boxed warning?
- No. None of the 20 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Bimatoprost?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Bimatoprost been recalled?
- FDA enforcement reports list 3 recalls of products of this medicine; the newest started October 17, 2019 (Class III). A recall usually concerns specific lots, not every product.
- Who makes Bimatoprost?
- 15 companies list prescription products of Bimatoprost in the FDA NDC Directory, including Fosun Pharma USA Inc., Gland Pharma Limited and Somerset Therapeutics, LLC.
What Bimatoprost is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
LATISSE ® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. LATISSE ® is a prostaglandin analog, indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.
— FDA label: Latisse, Allergan, Inc., effective July 1, 2024. Read the full label on DailyMed →
The FDA has 20 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 20 FDA labels for this medicine have a boxed warning.
Forms and how it is given
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| bimatoprost 0.1 mg/mL solution/ drops | Generic | $39.49–$43.46 per mL 6 packages, lowest to highest |
| bimatoprost 0.1 mg/mL solution/ drops | Brand: Lumigan | $102.93–$103.13 per mL 3 packages, lowest to highest |
| bimatoprost 0.3 mg/mL solution/ drops | Generic | $3.82–$26.63 per mL 19 packages, lowest to highest |
| bimatoprost 0.3 mg/mL solution/ drops | Brand: Latisse | $31.53–$40.97 per mL 2 packages, lowest to highest |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Fosun Pharma USA Inc.3 products
- Gland Pharma Limited3 products
- Somerset Therapeutics, LLC3 products
- Lifestar Pharma LLC3 products
- Allergan, Inc.3 products
- Alembic Pharmaceuticals Limited2 products
- Alembic Pharmaceuticals Inc.2 products
- NuCare Pharmaceuticals, Inc.2 products
- Apotex Corp.1 product
- First Nation Group, LLC1 product
- Sandoz Inc1 product
- Aurobindo Pharma Limited1 product
- Micro Labs Limited1 product
- Amneal Pharmaceuticals NY LLC1 product
- Thea Pharma Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA022184 LUMIGAN | Abbvie | August 31, 2010 | 7, latest March 8, 2022 2022: Labeling · 2020: Labeling · 2017: Labeling |
| NDA022369 LATISSE | Abbvie | December 24, 2008 | 11, latest August 26, 2021 2021: Labeling · 2020: Labeling · 2017: Labeling |
| NDA211911 DURYSTA | Abbvie | March 4, 2020 | 2, latest October 10, 2024 2024: Labeling · 2020: Labeling |
| NDA217307 ZOLYMBUS | Thea Pharma | September 9, 2025 | — |
Generic approvals (10)
- ANDA090449Apotex · July 20, 2015
- ANDA202719Sandoz · April 19, 2016
- ANDA210126Gland · March 22, 2019
- ANDA210263Alembic · April 12, 2019
- ANDA207601Somerset Theraps LLC · June 19, 2019
- ANDA210515Alembic · January 21, 2020
- ANDA202505Micro Labs · September 8, 2020
- ANDA205537Eugia Pharma · October 6, 2022
- ANDA218196Mankind Pharma · March 17, 2025
- ANDA217289Amneal · September 22, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
October 17, 2019 · Class III · Terminated · D-0161-2020
Labeling: Incorrect or missing package insert.
Bimatoprost Ophthalmic Solution 0.03%, Rx Only, For Topical Application to the Upper Eyelid, Sterile, a) 3 mL bottle NDC 0781-6206-93, b) 5 mL bottle NDC 0781-6206-75, Manufactured by Alcon Laboratories, Inc. Fort Worth, — Sandoz Inc
-
October 19, 2017 · Class III · Terminated · D-0078-2018
Failed Impurities/Degradation Specifications.
Lumigan (bimatoprost ophthalmic solution) 0.01%, 2.5 mL bottle, Rx only, Allergan, Irvine, CA 92612. NDC# 0023-3205-03 — Allergan Sales, LLC
-
March 16, 2017 · Class III · Terminated · D-0667-2017
Failed Impurities/Degradation Specifications
Lumigan (bimatoprost ophthalmic solution) 0.01%, 7.5 mL bottle, Rx only, Allergan Irvine, CA 92612, NDC 0023-3205-08. — Allergan Sales, LLC
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Latisse, Allergan, Inc., effective July 1, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →